In 2003, Radiometer was the world's leading supplier of blood gas analysis equipment and accessories for critical care patients. Based in Denmark, Radiometer sold through a mix of distributors and sales subsidiaries all over the world, and generated revenues of over DKr 1,791 million ($272 million). Blood gas evaluation formed part of the $27.7 billion in-vitro diagnostic market. Although sales were robust, Radiometer stayed focused on its future.
The marketplace for blood gas analysis was growing at a snail’s pace, driven primarily by new technologies that threatened to displace the high volume testing equipment that Radiometer supplied. Radiometer's recent attempts at competing in these brand new technologies had failed. Should it remain focused on blood gas evaluation and redouble its attempts? Or should it turn to other chances for growth? Controlling stockholder and CEO, Johan Schroder, had denied rumors of an expected sale, but an acquisition by a stronger partner could help the company grow into the United States. How should the firm place itself for future accomplishments?
Radiometer, 2003 Case Study Solution
PUBLICATION DATE: September 03, 2014 PRODUCT #: 715409-HCC-ENG
This is just an excerpt. This case is about STRATEGY & EXECUTION
PUBLICATION DATE: PRODUCT #:
Related Case Solutions & Analyses:
Making Effective Pricing Decisions
What Are Brands Good For
Integrated Marketing Midterm Exam
Talent Retention & Development in Albertas O&G Sector
The misplaced controversy about internal consumption: Not just a direct selling phenomenon
Telma: Building and Defending a Market Leader
The Mulliez Family Venture
Ethiopia: An Emerging Market Opportunity?
State Bank of India: Transforming a State Owned Giant
Customer Loyalty Schemes in the Retail Sector
